StockData
Soligenix, Inc. logo

Soligenix, Inc. (SNGX) stock

SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.28−0.01 (-2.67%)

Close on Nov 17, 2026Market cap $6.11MP/E –Yield –

Soligenix r&d expenses

Research and development expenses are spending on new products and technology.

Soligenix's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.62M, down 8.6% year over year. For fiscal 2025 it was $7.49M, up 43.3% from the year before. Over ten years it grew 3.3% a year on average. The highest annual figure on record is $9.80M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.49M+43.3%
FY2024Dec 31, 2024$5.22M+57.7%
FY2023Dec 31, 2023$3.31M-58.3%
FY2022Dec 31, 2022$7.94M-3.0%
FY2021Dec 31, 2021$8.19M-16.4%
FY2020Dec 31, 2020$9.80M+20.6%
FY2019Dec 31, 2019$8.12M+20.3%
FY2018Dec 31, 2018$6.75M+22.6%
FY2017Dec 31, 2017$5.51M+28.2%
FY2016Dec 31, 2016$4.30M-20.4%
FY2015Dec 31, 2015$5.40M+6.2%
FY2014Dec 31, 2014$5.09M+0.3%
FY2013Dec 31, 2013$5.07M+94.4%
FY2012Dec 31, 2012$2.61M-58.4%
FY2011Dec 31, 2011$6.27M+4.8%
FY2010Dec 31, 2010$5.99M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$974.09K-41.9%
Q1 FY2026Mar 31, 2026$1.78M-8.2%
Q4 FY2025Dec 31, 2025$2.28M-14.1%
Q3 FY2025Sep 30, 2025$1.58M+63.5%
Q2 FY2025Jun 30, 2025$1.68M+234.6%
Q1 FY2025Mar 31, 2025$1.94M+77.3%
Q4 FY2024Dec 31, 2024$2.66M+241.9%
Q3 FY2024Sep 30, 2024$968.69K+17.3%
Q2 FY2024Jun 30, 2024$501.16K-34.3%
Q1 FY2024Mar 31, 2024$1.10M+15.7%
Q4 FY2023Dec 31, 2023$777.53K-67.0%
Q3 FY2023Sep 30, 2023$826.02K-53.9%
Q2 FY2023Jun 30, 2023$762.70K-62.8%
Q1 FY2023Mar 31, 2023$946.45K-45.8%
Q4 FY2022Dec 31, 2022$2.36M-12.7%
Q3 FY2022Sep 30, 2022$1.79M-19.9%
Q2 FY2022Jun 30, 2022$2.05M+5.7%
Q1 FY2022Mar 31, 2022$1.75M+33.4%
Q4 FY2021Dec 31, 2021$2.70M-26.2%
Q3 FY2021Sep 30, 2021$2.24M+76.7%
Q2 FY2021Jun 30, 2021$1.94M-10.8%
Q1 FY2021Mar 31, 2021$1.31M-51.5%
Q4 FY2020Dec 31, 2020$3.66M+122.8%
Q3 FY2020Sep 30, 2020$1.27M-46.6%
Q2 FY2020Jun 30, 2020$2.17M+55.6%
Q1 FY2020Mar 31, 2020$2.70M+130.7%
Q1 FY2019Mar 31, 2019$1.64M-8.9%
Q4 FY2018Dec 31, 2018$2.37M+24.9%
Q3 FY2018Sep 30, 2018$1.39M+130.3%
Q2 FY2018Jun 30, 2018$1.17M-34.4%
Q1 FY2018Mar 31, 2018$1.80M+48.1%
Q4 FY2017Dec 31, 2017$1.90M+120.4%
Q3 FY2017Sep 30, 2017$605.72K-48.5%
Q2 FY2017Jun 30, 2017$1.78M+115.5%
Q1 FY2017Mar 31, 2017$1.22M-14.8%
Q4 FY2016Dec 31, 2016$862.27K–
Q3 FY2016Sep 30, 2016$1.18M–
Q2 FY2016Jun 30, 2016$827.83K–
Q1 FY2016Mar 31, 2016$1.43M–

More Soligenix figures

See a number that looks wrong?